[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. W. Marc Hertz Ph.D.", "age": 53, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 842014, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Albert  Agro Ph.d.", "age": 59, "title": "Co-Founder & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 461099, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leanne M. Kelly", "age": 47, "title": "CFO & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 550930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vipin  Kumar Chaturvedi Ph.D.", "age": 64, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cristina Gil White", "title": "Interim Chief Executive Officer of Global Reporting Initiative", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.54, "open": 0.53, "dayLow": 0.53, "dayHigh": 0.555, "regularMarketPreviousClose": 0.54, "regularMarketOpen": 0.53, "regularMarketDayLow": 0.53, "regularMarketDayHigh": 0.555, "trailingPE": 0.0070940284, "forwardPE": -0.5945946, "volume": 48659, "regularMarketVolume": 48659, "averageVolume": 248835, "averageVolume10days": 151460, "averageDailyVolume10Day": 151460, "bid": 0.528, "ask": 0.5642, "bidSize": 100, "askSize": 100, "marketCap": 4913353, "fiftyTwoWeekLow": 0.302, "fiftyTwoWeekHigh": 13.715, "fiftyDayAverage": 0.71002, "twoHundredDayAverage": 1.500465, "currency": "USD", "enterpriseValue": 298351, "floatShares": 8923093, "sharesOutstanding": 8933370, "sharesShort": 348603, "sharesShortPriorMonth": 272751, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.039, "heldPercentInsiders": 0.00115, "heldPercentInstitutions": 0.02506, "shortRatio": 2.0, "shortPercentOfFloat": 0.039100002, "impliedSharesOutstanding": 8933370, "bookValue": 0.729, "priceToBook": 0.7544582, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -8263000, "trailingEps": 77.53, "forwardEps": -2.63, "lastSplitFactor": "1:13", "lastSplitDate": 1718668800, "enterpriseToEbitda": -0.036, "52WeekChange": -0.95717686, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "messageBoardId": "finmb_136941170", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.55, "targetHighPrice": 13.0, "targetLowPrice": 10.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 4746000, "totalCashPerShare": 0.531, "ebitda": -8303000, "totalDebt": 131000, "quickRatio": 2.767, "currentRatio": 3.104, "debtToEquity": 3.579, "returnOnAssets": -1.0527999, "returnOnEquity": -2.8072, "freeCashflow": -5205875, "operatingCashflow": -12172000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]